wire - news in brief
Category
Results 151 - 200 of 367.
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Summit in the field of Additive Manufacturing
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Additive Manufacturing summit
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
Congratulations to the FMI Prize winners 2018
As in previous years, several internal prizes were awarded during the FMI Annual Meeting, a 3 day scientific meeting attended by most scientists in the institute.
As in previous years, several internal prizes were awarded during the FMI Annual Meeting, a 3 day scientific meeting attended by most scientists in the institute.
Even Small Gifts Boost Business
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse
FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam
Jacques Lévy has been awarded the 2018 Vautrin-Lud Prize, a geography award modeled on the Nobel Prize.
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with l
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with l
Empa is expanding its Coating Competence Center (CCC) thanks to a new partnership in the field of printed electronics with US-based equipment manufacturer Optomec.
On September 30, 2016, the active phase of the ESA's Rosetta mission came to an end with the controlled crash landing of the probe on the surface of the comet Chury.
Fructose metabolism and noncommunicable diseases: recent findings and new research perspectives
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).
French Recommendations for Sugar Intake in Adults: A Novel Approach Chosen by ANSES
Tappy L., Morio B., Azzout-Marniche D., Champ M., Gerber M., Houdart S., Mas E., Rizkalla S., Slama G., Mariotti F., Margaritis I..
Tappy L., Morio B., Azzout-Marniche D., Champ M., Gerber M., Houdart S., Mas E., Rizkalla S., Slama G., Mariotti F., Margaritis I..
The use of pesticides is still widespread in Swiss agriculture - and the resulting damage to humans and the environment is immense.
Smart transportation systems need smart governance
Two EPFL researchers have just published a book highlighting the need for cities to adopt adequate governance mechanisms for their transportation systems.
Two EPFL researchers have just published a book highlighting the need for cities to adopt adequate governance mechanisms for their transportation systems.
Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cancer (NSCLC), including those whose disease had spread to the central nervous system (CNS) Data will be submitted to glo
Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cancer (NSCLC), including those whose disease had spread to the central nervous system (CNS) Data will be submitted to glo
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic t
Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic t
Sharing data online: an innovative solution to respect and protect privacy
Insights from research at HEC Lausanne-UNIL - While respect for privacy is increasingly undermined on the web by publishing and sharing personal data, the solution for web actors developed by Prof&pe
Insights from research at HEC Lausanne-UNIL - While respect for privacy is increasingly undermined on the web by publishing and sharing personal data, the solution for web actors developed by Prof&pe
Facts and figures on Switzerland’s participation in the European Framework Programmes for Research
Bern, 20.09.2018 - The State Secretariat for Education, Research and Innovation (SERI) today published a report on Switzerland's involvement in the eighth European Framework Programme for Research and Innovation (Horizon 2020; 2014-2020).
Bern, 20.09.2018 - The State Secretariat for Education, Research and Innovation (SERI) today published a report on Switzerland's involvement in the eighth European Framework Programme for Research and Innovation (Horizon 2020; 2014-2020).
Today, the University of Basel and ETH Zurich co-founded the Botnar Research Centre for Child Health (BRCCH) in Basel.
Banks Do too Little to Communicate Their Sustainable Investment Products
Less than one percent of the global population controls more than 50 percent of wealth. All over the world these wealthy investors have an increasing interest in investing their wealth sustainably, in accordance with socially responsible, environmentally friendly and ethical principles.
Less than one percent of the global population controls more than 50 percent of wealth. All over the world these wealthy investors have an increasing interest in investing their wealth sustainably, in accordance with socially responsible, environmentally friendly and ethical principles.